Key clinical point: Dapagliflozin was safe and effective in patients with chronic kidney disease with an estimated glomerular filtration rate as low as 25 mL/min per 1.73m2.
Major finding: Dapagliflozin safely reduced the primary endpoint with a number needed to treat of 19 during a median of 2.4 years.
Study details: DAPA-CKD, a multicenter, randomized trial with 4,304 patients with chronic kidney disease.
Disclosures: DAPA-CKD was funded by AstraZeneca, the company that markets dapagliflozin. Dr. Heerspink has been a consultant to and received research funding from AstraZeneca. He has also received personal fees from Mundipharma and Novo Nordisk, and he has also served as consultant to several other companies with the honoraria being paid to his institution. Dr. Wheeler has received personal fees from AstraZeneca and from several other companies.
Heerspink HJL et al. EASD 2020 and N Engl J Med. 2020 Sep 24. doi: 10.1056/NEJMoa2024816.